Partnerships

Home / Partnerships
Slide background

A New Era of Medicine

Partnerships

HealthTell partners with industry to resolve unique issues across early discovery, clinical development and personal health. We have demonstrated our successful partnering with leading biopharmaceutical companies in the industry and most recently, HealthTell joined the Digital Life Alliance.

At HealthTell we recognize the tremendous impact the biotechnology sector has on improving outcomes for patients through innovation.  We applaud the remarkable progress that the industry is making through a) identifying aspects of Immune System pathophysiology that definitively effect the course of disease, and b) delivering immunological interventional therapies that confer truly curative power. 

As the Immuno-therapeutic revolution proceeds, HealthTell is a trusted and valuable partner for both diagnostic and therapeutic innovators providing unparalleled Immunomics insights and monoclonal antibody characterization and development.

Rational Discovery

HealthTell creates a collaborative partnership beyond discovery of initial mAb candidates and provides milestones to recognize probability of success, sharing risks with our biopharmaceutical partners.

Our Rational Discovery libraries provide unprecedented perspective to inform biotherapeutic discovery campaigns.  The most comprehensive diverse libraries are used to survey binding across pan-proteome sequence space.  The high-resolution epitope binning and mapping of on-target, and off-target binding events drive discovery campaigns to higher quality optimized lead candidates while uniquely informing design of protein-specific libraries. 

Protein-specific libraries (antigen, antigen-related proteins, etc.) are used to inform proprietary immunogen designs and to ensure specificity throughout lead optimization and developability.  Starting points can be flexible. We can begin by analyzing potentially thousands of antibodies or confirm mAb Panels already identified potentially for production.

To learn more about how to partner with HealthTell, contact us!

ImmunoSignatures

HealthTell has numerous relationships with major biopharmaceutical firms to facilitate clinical drug development.
HealthTell’s ImmunoSignature libraries provide the capability to monitor a person’s humoral immune response by providing binding events indicative of both active immune system physiology and memory. 

ImmunoSignatures are accessible in many sample types and aid in biopharmaceutical trials by: informing patient selection, predicting response to therapeutics and indicating possible adverse events.   

Biopharmaceutical firms include HelathTell ImmunoSignature measurements as part of their clinical trial, starting as early as phase I- phase 4. Analysis of samples will be available in days or, as specified by clinical protocols.

  • Stratified Patients
  • Identifies Treatment Responders
  • Indicates Patients with Adverse Events

To learn more about how to partner with HealthTell, contact us!

Health Monitoring

In January, 2017, HealthTell became the Immunomics pillar of Digital Life Alliance , an artificial intelligence (AI) based health care platform founded by Shenzhen-based iCarbonX.

The vision is to build an ecosystem to monitor health by measuring an individual’s biology, psychology, and personal behavior. The first intelligent digital guide will be created, through artificial intelligence data mining which combines biologics: metabolomics, genomics, transcriptomics, immunomics (HealthTell) and patient reported outcomes.

The goal is to provide a personalized health management system which presents recommendations for a healthier lifestyle.

To learn more about how to partner with HealthTell,contact us!